• 1
    Thomas ED,Storb R,Clift RA, et al. Bone-marrow transplantation. N Engl J Med. 1975; 292: 832843,895–902.
  • 2
    Armitage JO. Bone marrow transplantation [review]. N Engl J Med. 1994; 330: 827838.
  • 3
    McSweeney PA,Niederwieser D,Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001; 97: 33903400.
  • 4
    Giralt S,Estey E,Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997; 89: 45314536.
  • 5
    Slavin S,Nagler A,Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91: 756763.
  • 6
    Kottaridis PD,Milligan DW,Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000; 96: 24192425.
  • 7
    Sandmaier BM,Maloney DG,Gooley TA, et al. Low dose TBI conditioning for hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: influence of fludarabine or cytoreductive autografts on outcome. Blood. 2002; 100 (pt 1): 145a. Abstract 544.
  • 8
    Maris MB,Niederwieser D,Sandmaier BM, et al. Nonmyeloablative hematopoietic stem cell transplants (NM-HSCT) using 10 HLA antigen matched unrelated donors (URDs) for patients (pts) with advanced hematologic malignancies. Blood. 2002; 100(pt 1): 76a. Abstract 275.
  • 9
    Corradini P,Tarella C,Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002; 99: 7582.
  • 10
    Giralt S,Thall PF,Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001; 97: 631637.
  • 11
    Gomez-Nunez M,Martino R,Caballero MD, et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant. 2004; 33: 477482.
  • 12
    Sayer HG,Kroger M,Beyer J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003; 31: 10891095.
  • 13
    Karnofsky DA,Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacleodCM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949: 191.
  • 14
    Sorror ML,Maris MB,Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood. 2004; 104: 961968.
  • 15
    Diaconescu R,Flowers CR,Storer B, et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood. 2004; 104: 15501558.
  • 16
    Sorror ML,Maris MB,Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106: 29122919.
  • 17
    Maloney DG,Molina AJ,Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003; 102: 34473454.
  • 18
    Maris MB,Niederwieser D,Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003; 102: 20212030.
  • 19
    Petersdorf EW,Gooley TA,Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998; 92: 35153520.
  • 20
    Boeckh M,Bowden RA,Gooley T,Myerson D,Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [letter to editor]. Blood. 1999; 93: 17811782.
  • 21
    Marr KA,Seidel K,Slavin M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000; 96: 20552061.
  • 22
    Boeckh M,Marr KA. Infection in hematopoietic stem cell transplantation. In: RubinRH,YoungLS, eds. Clinical Approach to Infection in the Compromised Host. New York: Kluwer Academic/Plenum Publishers; 2002: 527571.
  • 23
    Boeckh M,Gooley TA,Myerson D,Cunningham T,Schoch G,Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996; 88: 40634071.
  • 24
    Kanda Y,Mineishi S,Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 28: 689692.
  • 25
    Kahl C,Storer BE,Sandmaier BM, et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007; 110: 27442748.
  • 26
    Kalbfleisch JD,Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
  • 27
    Fleiss JL. The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons; 1999.
  • 28
    Kahl C,Storer B,Mielcarek M, et al. Relapse risk after nonmyeloablative hematopoietic cell transplantation for malignant diseases. Blood. 2005; 106 (pt 1): 207a. Abstract 703.
  • 29
    Baron F,Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol. 2007; 14: 145151.
  • 30
    de Lima M,Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome [review]. Semin Hematol. 2006; 43: 107117.
  • 31
    Goodwin JS,Hunt WC,Samet JM. A population-based study of functional status and social support networks of elderly patients newly diagnosed with cancer. Arch Intern Med. 1991; 151: 366370.
  • 32
    Balducci L,Beghe C. The application of the principles of geriatrics to the management of the older person with cancer [review]. Crit Rev Oncol Hematol. 2000; 35: 147154.
  • 33
    Sorror ML,Giralt S,Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007; 110: 46064613.
  • 34
    Baron F,Storb R,Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopietic cell transplantation. J Clin Oncol. 2006; 24: 41504157.
  • 35
    Baron F,Maris MB,Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005; 23: 19932003.
  • 36
    Deeg HJ,Storer BE,Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006; 12: 573584.
  • 37
    Kerbauy DMB,Chyou F,Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005; 11: 713720.
  • 38
    Scott BL,Sandmaier BM,Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006; 20: 128135.
  • 39
    Giles F,Rizzieri D,Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007; 25: 2531.
  • 40
    Giles FJ,Borthakur G,Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients older than 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007; 136: 624627.
  • 41
    Kovacsovics T,Hayes-Lattin B,Riegert K, et al. Validation of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after matched unrelated donor SCT. Biol Blood Marrow Transplant. 2007; 13( suppl 1): 94. Abstract 257.
  • 42
    Firat S,Byhardt RW,Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on 4 RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002; 54: 357364.
  • 43
    Extermann M,Overcash J,Lyman GH,Parr J,Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16: 15821587.
  • 44
    Fried LP,Bandeen-Roche K,Kasper JD,Guralnik JM. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol. 1999; 52: 2737.
  • 45
    Appelbaum FR,Gundacker H,Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107: 34813485.
  • 46
    van Spronsen DJ,Janssen-Heijnen ML,Breed WP,Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993–1996. Ann Hematol. 1999; 78: 315319.
  • 47
    Khouri IF,Saliba RM,Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001; 98: 35953599.
  • 48
    Michallet M,Bilger K,Garban F, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol. 2001; 19: 33403349.
  • 49
    Wong R,Shahjahan M,Wang X, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005; 11: 108114.
  • 50
    Corradini P,Zallio F,Mariotti J, et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol. 2005; 23: 66906698.
  • 51
    Witherspoon RP,Deeg HJ,Storer B,Anasetti C,Storb R,Appelbaum FR. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol. 2001; 19: 21342141.
  • 52
    Coughlin SS,Calle EE,Teras LR,Petrelli J,Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159: 11601167.
  • 53
    Abe S,Funato T,Takahashi S, et al. Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia. Tohoku J Exp Med. 2006; 209: 217228.
  • 54
    Calle EE,Rodriguez C,Walker-Thurmond K,Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 16251638.
  • 55
    Chiu BC,Gapstur SM,Greenland P,Wang R,Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15: 23482354.
  • 56
    Patapanian H,Graham S,Sambrook PN, et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol. 1988; 27: 4447.
  • 57
    Kwong YL,Au WY,Liang RH. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-. Cancer Genetics Cytogenet. 1998; 104: 9497.
  • 58
    Vineis P,Crosignani P,Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health. 2000; 54: 431436.
  • 59
    Chelghoum Y,Danaila C,Belhabri A, et al. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol. 2002; 13: 16211627.
  • 60
    Thomas X,Chelghoum Y. Cigarette smoking and acute leukemia [review]. Leuk Lymphoma. 2004; 45: 11031109.
  • 61
    Extermann M. Interaction between comorbidity and cancer [review]. Cancer Control. 2007; 14: 1322.
  • 62
    Martino R,Iacobelli S,Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006; 108: 836846.
  • 63
    Delgado J,Thomson K,Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006; 107: 17241730.
  • 64
    Peggs KS,Hunter A,Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005; 365: 19341941.
  • 65
    Shimoni A,Hardan I,Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006; 20: 322328.
  • 66
    de Lima M,Anagnostopoulos A,Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104: 865872.
  • 67
    Alyea EP,Kim HT,Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005; 105: 18101814.
  • 68
    Gupta V,Daly A,Lipton JH, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant. 2005; 11: 764772.
  • 69
    Peccatori J,Barkholt L,Demirer T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer. 2005; 104: 20992103.
  • 70
    van Besien K,Sobocinski KA,Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998; 92: 18321836.
  • 71
    Anderson JE,Litzow MR,Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience. J Clin Oncol. 1993; 11: 23422350.
  • 72
    Dreger P,Brand R,Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning [review]. Leukemia. 2003; 17: 841848.
  • 73
    van Besien K,Artz A,Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005; 23: 57285738.
  • 74
    Artz AS,Pollyea DA,Kocherginsky M, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006; 12: 954964.